Gilteritinib companion diagnostic - Astellas Pharma/ Invivoscribe Technologies

Drug Profile

Gilteritinib companion diagnostic - Astellas Pharma/ Invivoscribe Technologies

Alternative Names: ASP 2215 hemifumarate companion diagnostic - Astellas/Invivoscribe; Gilteritinib fumarate companion diagnostic - Astellas/Invivoscribe

Latest Information Update: 16 Feb 2016

Price : $50

At a glance

  • Originator Astellas Pharma; Invivoscribe Technologies
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Acute myeloid leukaemia

Most Recent Events

  • 28 Apr 2015 Invivoscribe Technologies and Astellas Pharma enter into a collaboration to develop and commercialise a Gilteritinib companion diagnostic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top